To discuss the latest surgical and nonsurgical approaches to treating presbyopia, emphasizing the critical role of patient selection and expectation management in achieving optimal outcomes.
Key Findings:
Presbyopia affects nearly 130 million Americans and typically begins in the early to mid-40s.
Different refractive errors and patient goals significantly influence treatment options, necessitating a tailored approach.
Innovative intraocular lens technologies, such as multifocal and extended depth of focus lenses, are available but come with risks, including potential retinal complications.
Interpretation:
Effective management of presbyopia requires a comprehensive understanding of individual patient needs, refractive errors, and age-related factors to tailor treatment options appropriately.
Limitations:
Some treatments, like phakic IOLs, are considered off-label for patients over 45, which can complicate treatment decisions.
Many presbyopia drops are not FDA approved and cannot be offered yet, limiting options for patients.
Adaptation to multifocal lenses varies among patients, and some may require additional procedures, highlighting the need for careful patient selection.
Conclusion:
A comprehensive understanding of patient expectations and the limitations of available technologies is crucial for successful presbyopia treatment, ensuring that patients are well-informed and prepared for their options.
Eric Donnenfeld, MD, FACS explains how technologies to correct astigmatism can dramatically improve patient satisfaction and uncorrected visual acuity.
